BillionToOne Study Validates cfDNA Testing for General-Risk Pregnancies

The study, which achieved a 98.6% outcome ascertainment rate, evaluated the performance of BillionToOne's Unity Fetal Risk Screen in a general-risk population. Unlike previous research often enriched with high-risk couples, this data reflects routine clinical usage. The assay achieved 94.4% sensitivity, proving more reliable than standard carrier screening, which frequently fails due to incomplete partner testing or logistical barriers. By assessing fetal risk directly rather than relying on parental genotypes, the test provides a clearer diagnostic picture, offering quantitative risk assessments that range from 9-in-10 to 1-in-10,000.

Clinicians emphasize that the high level of outcome completeness makes these findings significant for everyday practice. Eliza McElwee, MD, of the Medical University of South Carolina, noted that the results provide a robust evidence base for integrating cfDNA assessment into standard prenatal care. Furthermore, the test demonstrated consistent performance across racially and ethnically diverse populations. Haywood Brown, MD, Chief Medical Officer at BillionToOne, stated that this performance ensures high-risk pregnancies are less likely to be overlooked simply because a partner sample remains uncollected. The company continues to expand its prenatal portfolio, recently announcing a new 130-gene panel to further advance comprehensive fetal risk evaluation.